Lantern Pharma Reports Q2 2025 Results with Clinical Trial Progress and AI Platform Enhancements

Lantern Pharma Inc. (NASDAQ: LTRN) reported second-quarter 2025 results highlighting substantial progress across its clinical development pipeline and artificial intelligence platform. The company completed enrollment of 65 patients in its Phase 1a trial of LP-184, establishing both the maximum tolerated dose and recommended Phase 2 dose, which enables planned Phase 1b/2 trials in recurrent triple negative breast cancer and other difficult-to-treat malignancies. Early patient responses observed across LP-184, LP-284, and LP-300 clinical trials demonstrate promising clinical activity in cancers with significant unmet medical needs.

The company strengthened its intellectual property portfolio with a new European patent allowance for LP-284 and the publication of a blood-brain barrier prediction patent. These developments provide additional protection for Lantern's drug candidates and enhance their commercial potential. The RADR® artificial intelligence platform saw notable enhancements, including the public launch of predictBBB.ai™, which leverages machine learning to predict drug penetration across the blood-brain barrier, and the introduction of a new drug combination module that identifies synergistic treatment approaches.

Financially, Lantern ended the second quarter with $15.9 million in cash, with management expecting the runway to extend into mid-2026. Research and development expenses declined year-over-year, reflecting disciplined cost control while advancing multiple clinical trials. The company's balance sheet provides funding stability as it progresses its oncology drug candidates targeting high-value markets. The clinical progress, combined with AI platform advancements and intellectual property gains, positions Lantern Pharma to potentially address significant oncology market opportunities while maintaining financial prudence.